{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:17:56Z","timestamp":1777047476755,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04390-3","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:52:37Z","timestamp":1756428757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The potential role of serum and urine galectin-3 values in the diagnosis and staging of Parkinson\u2019s disease"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-7816","authenticated-orcid":false,"given":"Miray","family":"Erdem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-1317","authenticated-orcid":false,"given":"Derya","family":"Ozdogru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0315-901X","authenticated-orcid":false,"given":"Elif Banu","family":"Soker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9551-3540","authenticated-orcid":false,"given":"Burak","family":"Ademoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-3100","authenticated-orcid":false,"given":"Nevzat","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1907-892X","authenticated-orcid":false,"given":"Onur Serdar","family":"Gencler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"4390_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134516","volume":"712","author":"S Sharma","year":"2019","unstructured":"Sharma S, Awasthi A, Singh S. Altered gut microbiota and intestinal permeability in Parkinson\u2019s disease: pathological highlight to management. Neurosci Lett. 2019;712:134516. https:\/\/doi.org\/10.1016\/j.neulet.2019.134516.","journal-title":"Neurosci Lett"},{"key":"4390_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.689723","volume":"15","author":"L Dumitrescu","year":"2021","unstructured":"Dumitrescu L, Marta D, D\u0103n\u0103u A, Lefter A, Tulb\u0103 D, Cozma L, et al. Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in Parkinson\u2019s disease. Front Neurosci. 2021;15:689723. https:\/\/doi.org\/10.3389\/fnins.2021.689723.","journal-title":"Front Neurosci"},{"issue":"7","key":"4390_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.26563","volume":"31","author":"CH Williams-Gray","year":"2016","unstructured":"Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, et al. Serum immune markers and disease progression in an incident parkinson\u2019s disease cohort (ICICLE-PD). Mov Disord. 2016;31(7):995\u20131003. https:\/\/doi.org\/10.1002\/mds.26563.","journal-title":"Mov Disord"},{"issue":"7","key":"4390_CR4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cells12071012","volume":"12","author":"S Isik","year":"2023","unstructured":"Isik S, Yeman Kiyak B, Akbayir R, Seyhali R, Arpaci T. Microglia mediated neuroinflammation in Parkinson\u2019s disease. Cells. 2023;12(7):1012. https:\/\/doi.org\/10.3390\/cells12071012.","journal-title":"Cells"},{"issue":"1","key":"4390_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00401-023-02585-x","volume":"146","author":"J Garc\u00eda-Revilla","year":"2023","unstructured":"Garc\u00eda-Revilla J, Boza-Serrano A, JinY, Vadukul DM, Sold\u00e1n-Hidalgo J, et al. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson\u2019s disease. Acta Neuropathol. 2023;146(1):51\u201375. https:\/\/doi.org\/10.1007\/s00401-023-02585-x.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"4390_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/biom10030389","volume":"10","author":"A Hara","year":"2020","unstructured":"Hara A, Niwa M, Noguchi K, Kanayama T, Niwa A, et al. Galectin-3 as a next generation biomarker for detection of early stages of various diseases. Biomolecules. 2020;10(3):389. https:\/\/doi.org\/10.3390\/biom10030389.","journal-title":"Biomolecules"},{"issue":"12","key":"4390_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"issue":"1","key":"4390_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mds.870090112","volume":"9","author":"P Mart\u00ednez-Mart\u00edn","year":"1994","unstructured":"Mart\u00ednez-Mart\u00edn P, Gil-Nagel A, Gracia LM, G\u00f3mez JB, Mart\u00ednez-Sarri\u00e9s J, The cooperative multicentric group, et al. Unified parkinson\u2019s disease rating scale characteristics and structure. Mov Disord. 1994;9(1):76\u201383. https:\/\/doi.org\/10.1002\/mds.870090112.","journal-title":"Mov Disord"},{"issue":"5","key":"4390_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342. https:\/\/doi.org\/10.1212\/wnl.17.5.427.","journal-title":"Neurology"},{"issue":"13","key":"4390_CR10","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, et al. The metric properties of a novel nonmotor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901\u201311. https:\/\/doi.org\/10.1002\/mds.21596.","journal-title":"Mov Disord"},{"issue":"15","key":"4390_CR11","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25(15):2649\u201353. https:\/\/doi.org\/10.1002\/mds.23429.","journal-title":"Mov Disord"},{"key":"4390_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jocn.2019.08.032","volume":"70","author":"HO Yazar","year":"2019","unstructured":"Yazar HO, Yazar T, Cihan M. A preliminary data: evaluation of serum Galectin-3 levels in patients with idiopathic Parkinson\u2019s disease. J Clin Neurosci. 2019;70:164\u20138. https:\/\/doi.org\/10.1016\/j.jocn.2019.08.032.","journal-title":"J Clin Neurosci"},{"key":"4390_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105373","volume":"184","author":"T Cengiz","year":"2019","unstructured":"Cengiz T, Turkboylar\u0131 S, Gen\u00e7ler OS, Anlar O. The roles of galectin-3 and galectin-4 in the idiopatic Parkinson disease and its progression. Clin Neurol Neurosurg. 2019;184:105373. https:\/\/doi.org\/10.1016\/j.clineuro.2019.105373.","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"4390_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11111515","volume":"11","author":"HC Wu","year":"2021","unstructured":"Wu HC, Chang KH, Chiang MC, Chen CM. Alterations of plasma Galectin-3 and C3 levels in patients with Parkinson\u2019s disease. Brain Sci. 2021;11(11):1515. https:\/\/doi.org\/10.3390\/brainsci11111515.","journal-title":"Brain Sci"},{"issue":"2","key":"4390_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3892\/ijmm.2017.3311","volume":"41","author":"R Dong","year":"2018","unstructured":"Dong R, Min Z, Hu Q, Zheng S, Soh A, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy(Review). Int J Mol Med. 2018;41(2):599\u2013614. https:\/\/doi.org\/10.3892\/ijmm.2017.3311.","journal-title":"Int J Mol Med"},{"key":"4390_CR16","doi-asserted-by":"publisher","first-page":"706439","DOI":"10.3389\/fphar.2021.706439","volume":"12","author":"AW Espinosa-Oliva","year":"2021","unstructured":"Espinosa-Oliva AW, Garcia-Miranda P, Alonso-Bellido IM, Carvajal AE, Gonz\u00e1lez-Rodr\u00edguez M, et al. Galectin-3 deletion reduces LPS and acute Colitis-Induced Pro-Inflammatory microglial activation in the ventral mesencephalon. Front Pharmacol. 2021;12:706439. https:\/\/doi.org\/10.3389\/fphar.2021.706439.","journal-title":"Front Pharmacol"},{"key":"4390_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00398","volume":"12","author":"I Garcia-Dominguez","year":"2018","unstructured":"Garcia-Dominguez I, Vesela K, Garcia-Revilla J, et al. Peripheral inflammation enhances microglia response and nigral dopaminergic cell death in an in vivo MPTP model of Parkinson\u2019s disease. Front Cell Neurosci. 2018;12:398. https:\/\/doi.org\/10.3389\/fncel.2018.00398.","journal-title":"Front Cell Neurosci"},{"issue":"9","key":"4390_CR18","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.4103\/1673-5374.391181","volume":"19","author":"BM Lozinski","year":"2024","unstructured":"Lozinski BM, Ta K, Dong Y. Emerging role of galectin 3 in neuroinflammation and neurodegeneration. Neural Regen Res. 2024;19(9):2004\u20139. https:\/\/doi.org\/10.4103\/1673-5374.391181.","journal-title":"Neural Regen Res"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04390-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:52:37Z","timestamp":1756428757000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04390-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4390"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04390-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Health Sciences University, Adana City Training and Research Hospital, at its meeting on 14 September 2023 (decision no 2822), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Our study was conducted in strict adherence to the Declaration of Helsinki, and written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}